AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure
Completed
- Conditions
- Blood Pressure
- First Posted Date
- 2009-06-22
- Last Posted Date
- 2009-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1200
- Registration Number
- NCT00925470
- Locations
- 🇫🇷
Research Site, Yvetot, France
Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients
Completed
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2011-09-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 186
- Registration Number
- NCT00922025
- Locations
- 🇨🇳
Research Site, Taipe, Taiwan
A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2009-06-17
- Last Posted Date
- 2010-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1494
- Registration Number
- NCT00922090
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS)
Completed
- Conditions
- Cardiovascular Risk
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2009-12-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT00921752
- Locations
- 🇭🇺
Research Site, Vac, Hungary
Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2010-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 296
- Registration Number
- NCT00921804
- Locations
- 🇺🇸
Research Site, Rockville, Maryland, United States
Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2009-06-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1387
- Registration Number
- NCT00921362
A Study to Assess the Pharmacokinetics of Methotrexate Given With and Without AZD9056 in Rheumatoid Arthritis Patients
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT00920608
Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients
- First Posted Date
- 2009-06-12
- Last Posted Date
- 2010-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT00919607
- Locations
- 🇨🇳
Research Site, Beijing, Beijing, China
Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mg
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2009-06-12
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 712
- Registration Number
- NCT00919477
- Locations
- 🇯🇵
Research Site, Yamagata, Japan
Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 213
- Registration Number
- NCT00918879
- Locations
- 🇮🇳
Research Site, Maharashtra, Pune, India